Rishu Agarwal1, Stephen Lade1, Danny Liew2, Toni-Maree Rogers1, David Byrne1, Frank Feleppa3, Surender Juneja2, David A Westerman4. 1. Division of Cancer Medicine, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 2. Department of Diagnostic Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia University of Melbourne, Department of Pathology, Parkville, Victoria, Australia. 3. Department of Diagnostic Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia. 4. Division of Cancer Medicine, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia University of Melbourne, Department of Pathology, Parkville, Victoria, Australia.
Abstract
AIMS: MYC rearrangements with or without BCL2 rearrangements have been shown to be associated with poor prognosis and inferior survival in diffuse large B-cell lymphomas (DLBCL). Most of these cases are still diagnosed by fluorescent in situ hybridisation (FISH) testing, which is expensive, requires expertise and is not routinely available in all laboratories. Immunohistochemistry (IHC) is widely available and has the potential to be used as a screening test to identify cases with increased protein expression and select cases that require confirmatory testing. We correlated the expression of MYC and BCL2 by IHC with FISH studies in an attempt to define a cut-off value, which can be used by laboratories to select cases requiring confirmatory FISH testing. The prevalence of MYC-positive DLBCL and double-hit lymphoma (DHL) has also been studied. METHODS: 209 cases comprising of 15 cases of Burkitt lymphoma (BL), 13 cases of intermediate BL/DLBCL and 181 cases of DLBCL were included. IHC and FISH for MYC and BCL2 were performed and the results were correlated. RESULTS: The prevalence of MYC-positive DLBCL and MYC/BCL2DHL was 13.4% and 7.4%, respectively, in our study. Germinal-centre subtype was more common in MYC-positive DLBCL and DHL. MYC-positive DLBCL also showed higher median Ki-67 (>90%) and CD10 positivity as compared with MYC-negative cases. CONCLUSIONS: IHC can be used for screening cases, which require further confirmatory FISH testing. We recommend a cut-off value of ≥30% for MYC by IHC; however, international standardisation of these values is necessary to provide uniformity among laboratories. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
AIMS: MYC rearrangements with or without BCL2 rearrangements have been shown to be associated with poor prognosis and inferior survival in diffuse large B-cell lymphomas (DLBCL). Most of these cases are still diagnosed by fluorescent in situ hybridisation (FISH) testing, which is expensive, requires expertise and is not routinely available in all laboratories. Immunohistochemistry (IHC) is widely available and has the potential to be used as a screening test to identify cases with increased protein expression and select cases that require confirmatory testing. We correlated the expression of MYC and BCL2 by IHC with FISH studies in an attempt to define a cut-off value, which can be used by laboratories to select cases requiring confirmatory FISH testing. The prevalence of MYC-positive DLBCL and double-hit lymphoma (DHL) has also been studied. METHODS: 209 cases comprising of 15 cases of Burkitt lymphoma (BL), 13 cases of intermediate BL/DLBCL and 181 cases of DLBCL were included. IHC and FISH for MYC and BCL2 were performed and the results were correlated. RESULTS: The prevalence of MYC-positive DLBCL and MYC/BCL2DHL was 13.4% and 7.4%, respectively, in our study. Germinal-centre subtype was more common in MYC-positive DLBCL and DHL. MYC-positive DLBCL also showed higher median Ki-67 (>90%) and CD10 positivity as compared with MYC-negative cases. CONCLUSIONS: IHC can be used for screening cases, which require further confirmatory FISH testing. We recommend a cut-off value of ≥30% for MYC by IHC; however, international standardisation of these values is necessary to provide uniformity among laboratories. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Mark Bosch; Ariz Akhter; Bingshu E Chen; Adnan Mansoor; David Lebrun; David Good; Michael Crump; Lois Shepherd; David W Scott; Douglas A Stewart Journal: Haematologica Date: 2017-11-02 Impact factor: 9.941
Authors: Xaver U Kahle; Menno Hovingh; Walter Noordzij; Annika Seitz; Arjan Diepstra; Lydia Visser; Anke van den Berg; Tom van Meerten; Gerwin Huls; Ronald Boellaard; Thomas C Kwee; Marcel Nijland Journal: Eur Radiol Date: 2019-04-26 Impact factor: 5.315
Authors: Igor Aurer; Martin Dreyling; Massimo Federico; Herve Tilly; Kim Linton; Eva Kimby; Martine E D Chamuleau; Marie Jose Kersten Journal: Hemasphere Date: 2020-10-20